These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 17868014)

  • 1. Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances.
    Smith PF
    Expert Rev Neurother; 2007 Sep; 7(9):1157-63. PubMed ID: 17868014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.
    Smith PF
    Curr Opin Investig Drugs; 2002 Jun; 3(6):859-64. PubMed ID: 12137404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of cannabinoids for the treatment of multiple sclerosis.
    Smith PF
    Expert Opin Drug Saf; 2005 May; 4(3):443-56. PubMed ID: 15934852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicinal cannabis extracts for the treatment of multiple sclerosis.
    Smith PF
    Curr Opin Investig Drugs; 2004 Jul; 5(7):727-30. PubMed ID: 15298068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment of pain in multiple sclerosis.
    Solaro C; Tanganelli P; Messmer Uccelli M
    Expert Rev Neurother; 2007 Sep; 7(9):1165-74. PubMed ID: 17868015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cannabinoids in multiple sclerosis -- therapeutically reasonable?].
    Trebst C; Stangel M
    Fortschr Neurol Psychiatr; 2005 Aug; 73(8):463-9. PubMed ID: 16052440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabis derivatives and pain. A small role for delta9-tetrahydrocannabinol (THC) in some forms of multiple sclerosis.
    Prescrire Int; 2009 Oct; 18(103):226. PubMed ID: 19882800
    [No Abstract]   [Full Text] [Related]  

  • 9. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
    Rice J; Cameron M
    Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the roles of cannabinoids in pain and other therapeutic indications: a review.
    Turcotte D; Le Dorze JA; Esfahani F; Frost E; Gomori A; Namaka M
    Expert Opin Pharmacother; 2010 Jan; 11(1):17-31. PubMed ID: 20001426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
    Pozzilli C
    Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
    Aragona M; Onesti E; Tomassini V; Conte A; Gupta S; Gilio F; Pantano P; Pozzilli C; Inghilleri M
    Clin Neuropharmacol; 2009; 32(1):41-7. PubMed ID: 18978501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.
    Russo EB; Guy GW; Robson PJ
    Chem Biodivers; 2007 Aug; 4(8):1729-43. PubMed ID: 17712817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
    Vermersch P
    Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in the therapeutic potential of cannabinoids.
    Corey S
    P R Health Sci J; 2005 Mar; 24(1):19-26. PubMed ID: 15895873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids in medicine: A review of their therapeutic potential.
    Ben Amar M
    J Ethnopharmacol; 2006 Apr; 105(1-2):1-25. PubMed ID: 16540272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
    Oreja-Guevara C
    Expert Rev Neurother; 2012 Apr; 12(4 Suppl):3-8. PubMed ID: 22509985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.
    Russo E; Guy GW
    Med Hypotheses; 2006; 66(2):234-46. PubMed ID: 16209908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Bazinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
    Moreno Torres I; Sanchez AJ; Garcia-Merino A
    Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.